Suppr超能文献

腹透液轻度减钠可改善终末期肾病高血压:病例报告研究。

Mild sodium reduction in peritoneal dialysis solution improves hypertension in end stage kidney disease: a case-report study.

机构信息

Unit of Nephrology, Santa Maria Hospital, Terni, Italy.

Department of Medicine, Section of Nephrology and Dialysis, G. d'Annunzio University, Chieti-Pescara, Chieti, Italy.

出版信息

BMC Nephrol. 2021 May 8;22(1):170. doi: 10.1186/s12882-021-02380-4.

Abstract

INTRODUCTION

Blood Pressure (BP) control is largely unsatisfied in End Stage Kidney Disease (ESKD) principally due to sodium retention. Peritoneal Dialysis (PD) is the most common type of home dialysis, using a peritoneal membrane to remove sodium, though sodium removal remains challenging.

METHODS

This is a case-study reporting two consecutive ESKD patients treated by a novel peritoneal PD solution with a mildly reduced sodium content (130 mmol/L) to treat hypertension.

RESULTS

In the first case, a 78-year-old woman treated by Continuous Ambulatory PD (CAPD) with standard solution (three 4 h-dwells per day 1.36% glucose 132 mmol/L) showed resistant hypertension confirmed by ambulatory blood pressure monitoring (ABPM), reporting 24 h-BP: 152/81 mmHg, day-BP:151/83 mmHg and night-ABP: 153/75 mmHg, with inversion of the circadian systolic BP rhythm (1.01), despite use of three anti-hypertensives and a diuretic at adequate doses. No sign of hypervolemia was evident. We then switched from standard PD to low-sodium solution in all daily dwells. A six-months low-sodium CAPD enabled us to reduce diurnal (134/75 mmHg) and nocturnal BP (122/67 mmHg), restoring the circadian BP rhythm, with no change in ultrafiltration or residual diuresis. Diet and drug prescription were unmodified too. The second case was a 61-year-old woman in standard CAPD (three 5 h-dwells per day) suffering from hypertension confirmed by ABPM (mean 24 h-ABP: 139/84 mmHg; mean day-ABP:144/88 mmHg and mean night-ABP:124/70 mmHg). She was switched from 132-Na CAPD to 130-Na CAPD, not changing dialysis schedule. No fluid expansion was evident. During low-sodium CAPD, antihypertensive therapy (amlodipine 10 mg and Olmesartan 20 mg) has been reduced until complete suspension. After 6 months, we repeated ABPM showing a substantial reduction in mean 24 h-ABP (117/69 mmHg), mean diurnal ABP (119/75 mmHg) and mean nocturnal ABP (111/70 mmHg). Ultrafiltration and residual diuresis remained unmodified. No side effects were reported in either cases.

CONCLUSIONS

This case-report study suggests that mild low-sodium CAPD might reduce BP in hypertensive ESKD patients.

摘要

简介

在终末期肾病(ESKD)患者中,血压(BP)控制主要不满意,主要是由于钠潴留。腹膜透析(PD)是最常见的家庭透析类型,使用腹膜膜来去除钠,尽管去除钠仍然具有挑战性。

方法

这是一项病例研究,报告了两名连续的 ESKD 患者,他们使用一种新型的腹膜 PD 溶液进行治疗,该溶液的钠含量略低(130mmol/L),以治疗高血压。

结果

在第一个病例中,一名 78 岁的女性接受持续流动 PD(CAPD)治疗,使用标准溶液(每天 3 次 4 小时卧床,1.36%葡萄糖 132mmol/L),通过动态血压监测(ABPM)证实患有难治性高血压,报告 24 小时 BP:152/81mmHg,白天 BP:151/83mmHg,夜间 ABPM:153/75mmHg,且白天收缩压节律发生反转(1.01),尽管使用了三种降压药和一种利尿剂,但剂量足够。没有明显的血容量过多迹象。然后,我们将所有日常卧床的标准 PD 切换为低钠溶液。六个月的低钠 CAPD 使我们能够降低白天(134/75mmHg)和夜间血压(122/67mmHg),恢复昼夜血压节律,超滤和残余尿量无变化。饮食和药物处方也没有改变。第二个病例是一名 61 岁的女性,在标准 CAPD(每天 3 次 5 小时卧床)中患有高血压,通过 ABPM 证实(平均 24 小时 ABPM:139/84mmHg;平均日间 ABPM:144/88mmHg 和平均夜间 ABPM:124/70mmHg)。她从 132-Na CAPD 转换为 130-Na CAPD,未改变透析时间表。没有明显的液体扩张。在低钠 CAPD 期间,抗高血压治疗(氨氯地平 10mg 和奥美沙坦 20mg)已减少到完全停药。6 个月后,我们重复 ABPM 显示平均 24 小时 ABPM(117/69mmHg)、平均日间 ABPM(119/75mmHg)和平均夜间 ABPM(111/70mmHg)有显著降低。超滤和残余尿量无变化。在这两种情况下均未报告任何副作用。

结论

本病例报告研究表明,轻度低钠 CAPD 可能会降低高血压 ESKD 患者的血压。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b0e4/8105985/dd4cc24db29a/12882_2021_2380_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验